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SUMMARY
Next-generation sequencing of human tumours has refined our understanding of the mutational 
processes operative in cancer initiation and progression, yet major questions remain regarding 
factors that induce driver mutations, and the processes that shape their selection during 
tumourigenesis. We performed whole-exome sequencing (WES) on adenomas from three mouse 
models of non-small cell lung cancer (NSCLC), induced by exposure to carcinogens 
(Methylnitrosourea (MNU) and Urethane), or by genetic activation of Kras (KrasLA2). Although 
the MNU-induced tumours carried exactly the same initiating mutation in Kras as seen in the 
KrasLA2 model (G12D), MNU tumours had an average of 192 non-synonymous, somatic single 
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nucleotide variants (SNVs), compared to only 6 in tumours from the KrasLA2 model. In contrast, 
the KrasLA2 tumours exhibited a significantly higher level of aneuploidy and copy number 
alterations (CNAs) compared to the carcinogen-induced tumours, suggesting that carcinogen and 
genetically-engineered models adopt different routes to tumour development. The wild type (WT) 
allele of Kras has been shown to act as a tumour suppressor in mouse models of NSCLC. We 
demonstrate that urethane-induced tumours from WT mice carry mostly (94%) Q61R Kras 
mutations, while those from Kras heterozygous animals carry mostly (92%) Q61L mutations, 
indicating a major role of germline Kras status in mutation selection during initiation. The exome-
wide mutation spectra in carcinogen-induced tumours overwhelmingly display signatures of the 
initiating carcinogen, while adenocarcinomas acquire additional C>T mutations at CpG sites. 
These data provide a basis for understanding the conclusions from human tumour genome 
sequencing that identified two broad categories based on relative frequency of SNVs and CNAs1, 
and underline the importance of carcinogen models for understanding the complex mutation 
spectra seen in human cancers.
Sequencing studies of human cancers have identified a number of mutation “signatures”, 
suggesting that tumours carry an imprint of the environmental agents to which patients were 
exposed2-4. There are presently no studies of genome-wide carcinogen signatures in any 
mouse cancer models, despite widespread use of these models in studies of cancer. To 
address the importance of engineered versus carcinogen-induced mutations, we investigated 
the mutations in mouse NSCLC arising as a result of spontaneous oncogenic activation of 
Kras (KrasLA2)5, or exposure to urethane or MNU6. Both carcinogens initiate lung 
tumourigenesis by oncogenic mutation of Kras, which is frequently mutated in human 
NSCLC7. WES was performed on 82 FVB/N lung adenomas, 44 induced by urethane, 26 by 
MNU, and 12 by the KrasLA2 allele (Extended Data Table 1). To study the tumour 
suppressive role of WT Kras, we included mice with one functionally null Kras allele, 
Kras+/LSL-G12D (see Methods)8, hereafter referred to as Kras+/−. Importantly, these mice 
develop larger and more tumours than WT littermates following carcinogen treatment9,10.
Carcinogen-induced tumours had far more SNVs than KrasLA2 tumours (Fig. 1a), with an 
average of 728 and 185 in MNU- and urethane-induced tumours, respectively, and 47 in 
KrasLA2 tumours. This is similar to findings in humans where lung tumours from smokers 
contained orders of magnitude more SNVs than tumours from non-smokers11. We 
performed hierarchical clustering on the 96 possible SNVs, classified by trinucleotide 
context and substitution3, and tumours cluster perfectly by treatment (Fig. 1b), underscoring 
distinct mutational spectra. Highly consistent signatures are apparent across all tumours of 
each carcinogen group (Fig. 1c and Extended Data Fig. 1a-b), in agreement with the known 
A>T, A>G, and G>A substitutions induced by urethane12, and G>A transitions induced by 
MNU13. The elevated SNV burden and clear carcinogen imprint show that most SNVs were 
induced during the period of carcinogen activity following administration. In contrast, 
KrasLA2 tumours showed no notable signatures (Extended Data Fig. 1c).
A highly significant 5′-flanking purine bias and 3′-flanking thymidine bias for G>A 
transitions was identified in the MNU-induced tumours (Extended Data Fig. 2a). Indeed, 
GGT>A is the most frequent SNV in this group. In urethane-induced tumours, a slight bias 
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for 3′-cytidine in A>G transitions and 3′-guanosine in A>T transversions was seen 
(Extended Data Fig. 2b-c), while G>A transitions were also common (Extended Data Fig. 
2d). The most frequent SNVs in KrasLA2 tumours were CGN>A (or the complement, 
NCG>T) (Extended Data Fig. 2e). Importantly, CGN>A is a signature of genomic instability 
in cancer and normal cells3,14,15.
In concordance with MNU’s propensity to induce GGT>A transitions, 25/26 MNU-induced 
lung tumours carried this transition in codon 12 of Kras, resulting in a G12D mutation, 
while all 44 urethane-induced tumours harbored Kras Q61 mutations (SI Table 1). 
Histological evaluation revealed the expected tumour types (Extended Data Fig. 3a), and 
solid tumours were significantly enriched in the MNU and KrasLA2 groups, which share the 
Kras G12D mutation (Extended Data Fig. 3b). It is possible that Kras G12D initiates a 
pathway to solid NSCLC that is distinct from that initiated by Q61 mutants. Alternatively, 
urethane may induce Kras mutations in a different population of tumour-initiating cells. 
Remarkably, urethane-induced tumours from WT mice had almost exclusively Kras Q61R 
mutations, while tumours from Kras+/− mice had almost exclusively Q61L mutations 
(Extended Data Fig. 4a-b). This switch is not likely due to differences in carcinogen 
metabolism or DNA repair, as neither the overall mutation spectra (Extended Data Fig. 1b) 
nor the exome-wide rates of the causative Q61R and Q61L substitutions (Extended Data 
Fig. 4c) differed between tumours of the two genotypes. This suggests that Kras Q61R and 
Q61L are functionally distinct, and selection of cells harboring these oncoproteins is 
modulated by WT Kras. Intriguingly, in the single instance of a Kras Q61L mutant tumour 
from a WT mouse, a Kras loss-of-function mutation (T35A)16,17 was also found, potentially 
inactivating the WT allele. Although KRAS Q61 mutations are relatively rare in human lung 
cancer, further investigation of the Q61 switch may yield valuable insights into RAS 
mutation selection, and the interplay of RAS oncogenes and their proto-oncogenes. While 
further studies are needed to identify the mechanism of this selection, we conclude that Kras 
mutations are not only carcinogen-dependent, but are influenced by germline differences 
that alter the expression of WT Kras.
We focused our search for additional driver mutations on genes known to harbor bona fide 
driver mutations in human cancers18,19 (see Methods). 65 consequential SNVs in 49 of these 
genes were validated (Extended Data Table 2), most involving amino acids conserved 
between mouse and human. SNVs in Akt1, Atm, Rnf43, Notch1, Ret, and Rb1, in particular, 
occurred at positions homologous to mutations in human cancers (SI Table 2). Two 
nonsense and two missense mutations were found in Mtus1, a candidate tumour suppressor 
gene in multiple cancers20-23. In concordance with its role as a tumour suppressor, 
knockdown of Mtus1 accelerated growth in a mouse lung cancer cell line driven by Kras 
G12D (Extended Data Fig. 5a-b). In addition, MTUS1 expression is significantly and 
positively associated with overall survival across all stages in human lung adenocarcinoma 
(TCGA LUAD RNA-seq, n = 354) (Extended Data Fig. 5c; SI Table 3). This association 
was validated in an independent human lung adenocarcinoma dataset24 (SI Table 3).
The observation that KrasLA2 tumours have on average 15-fold fewer SNVs than MNU-
induced tumours (Fig. 1b), despite sharing similar histology and the same Kras mutation, 
suggested there are additional factors influencing tumourigenesis in these samples. Indeed, 
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we found that CNAs are widespread in KrasLA2 tumours (average = 3.25) but infrequent in 
carcinogen-induced tumours (average = 0.07), and hierarchical clustering by copy-number 
profile clearly segregated the carcinogen-induced and KrasLA2 tumours into different groups 
(Fig. 2). Most KrasLA2 tumours (9/12) showed amplification of Kras, mainly via gain of one 
copy of chromosome 6. These tumours also carried common gains on chromosomes 2, 10, 
12, 15, and 17, and deletions on chromosomes 4, 9, 11, and 17 (Extended Data Fig. 6), 
consistent with previously published aCGH results from the KrasLA2 model25. In contrast, 
carcinogen-induced tumours had very few CNAs and aneuploidies.
A summary of SNVs and CNAs involving driver genes reveals that all SNVs occurred in 
carcinogen-induced tumours and overwhelmingly showed the signature of the initiating 
carcinogen (Fig. 3). This suggests that carcinogen models produce tumours with a diversity 
of potential secondary driver SNVs, recapitulating in part the mutational heterogeneity seen 
in human cancer. One MNU-induced tumour harbored an E40K mutation in Akt1, 
generating a constitutively active oncoprotein26, and an early nonsense mutation in the 
tumour suppressor gene Pax5. Together with Kras G12D, this tumour had three functional 
mutations in cancer drivers, all MNU signature mutations likely induced in the same cell 
following MNU treatment. Although the KrasLA2 tumours had no SNVs in established 
driver genes, some exhibited CNAs involving driver genes mutated in the carcinogen-
induced tumours (Fig. 3). Further evidence for the role of CNAs in genetically-engineered 
mouse models of cancer is provided by a recent report showing that mouse small-cell lung 
cancers induced by inactivation of Trp53 and Rb1 exhibit many CNAs, but a paucity of 
SNVs27. Similarly, mouse lung tumours induced by Cre-activation of KrasLSL-G12D exhibit 
extremely few exome-wide SNVs (personal communication, Tyler Jacks). We conclude that 
carcinogen and genetic models show fundamental differences in patterns of genomic 
alterations, and that the requirement for CNAs may be abrogated by the high frequency of 
carcinogen-induced SNVs—a reciprocal relationship also seen in a recent analysis of TCGA 
sequencing of several thousand human tumours1.
To understand the processes operative in progression to adenocarcinoma, we performed 
WES on 9 FVB/N and 13 A/J strain urethane-induced, histologically-confirmed lung 
adenocarcinomas (Extended Data Fig. 7a-b). The observed urethane-signature A>G and 
A>T substitutions recapitulate the rates and patterns seen in the adenomas with remarkable 
fidelity (Extended Data Fig. 8), validating the utility of mouse carcinogen models to resolve 
complex mutational spectra. Further analysis revealed a significant increase of the CGN>A 
signature of genomic instability in both FVB/N and A/J adenocarcinomas (Fig. 4). This 
elevation cannot be attributed solely to tumour age, as the FVB/N adenocarcinomas and 
adenomas were harvested following the same 20-week protocol.
Most adenocarcinomas harbored Q61R mutations in Kras (SI Table 4). Although urethane is 
known to induce Kras Q61L lung adenomas in A/J mice, adenocarcinomas from these 
animals harbor predominantly Kras Q61R mutations28. Eleven additional SNVs in driver 
genes were identified, as well as 3 SNVs in the reported mouse lung adenoma suppressor 
gene Fat429 (SI Table 5). Compared to the urethane-induced adenomas, the 
adenocarcinomas are enriched for tumours with SNVs in high-likelihood driver genes other 
than Kras (Fisher p = 0.046), as well as tumours harboring CGN>A transitions in these 
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genes (Fisher p = 0.034). These data suggest that CGN>A transitions may play a role in 
progression of adenomas to adenocarcinomas.
A comparison of all validated carcinogen-induced mouse mutations with WES of human 
lung adenocarcinoma (TCGA LUAD, n = 230) revealed substantial overlap in driver genes 
harboring consequential mutations, both overall and in KRAS-mutant tumours (SI Table 6). 
Some of the most frequently mutated genes in the mouse tumours (Arid1b, Atm, Crebbp, 
Mll2, Rb1) were also frequently mutated in the human tumours. Many of the mouse 
mutations occurred near mutations identified in TCGA LUAD, including functional 
mutations in Akt1, Atm, and Cbl (SI Table 7). In addition, the driver genes ALK, APC, JAK2, 
MET, and NF1, commonly mutated in human NSCLC11, were mutated in the mouse 
tumours. Finally, an analysis of MTUS1 mutations in TCGA LUAD revealed only 
consequential mutations (1.7%)—two missense mutations, and two frameshift deletions—
suggesting that loss-of-function mutations in MTUS1 may be selected for in a subset of lung 
adenocarcinomas.
Genomic analysis of mouse tumours induced by a range of carcinogens may help reveal the 
relationships between environmental exposures and tumour architecture. Models that 
encompass heterogeneity in both genetic background and carcinogen exposure may also be 
useful for preclinical testing of cancer therapeutics, as the diversity of germline and somatic 
SNVs may recapitulate variation in drug response and resistance observed in human clinical 
trials. Importantly, carcinogen models enable production of tumours with a range of 
initiating Ras lesions, providing a valuable resource for interrogating the specificity and 
idiosyncrasies of these different mutations.
METHODS
Mouse strains and tumour induction
KrasLA2 and KrasLSL-G12D alleles, originally on a C57BL6/129/SvJae background, were 
backcrossed onto the FVB/N genetic background for more than 20 generations. Mice were 
treated with urethane (1 g/kg) or MNU (50 mg/kg) dissolved in PBS by intraperitoneal 
injection at ~7-12 weeks of age. Lung tumours from mice induced with carcinogen were 
harvested at ~20 weeks after injection, or ~32 weeks in the A/J animals, while spontaneous 
lung tumours were collected from KrasLA2 mice at ~9 months of age. For the urethane-
induced adenomas, 18 tumours from 7 WT animals and 26 tumours from 9 KrasLSL-G12D 
animals were collected. For the MNU treatment group, 5 tumours from 4 WT animals and 21 
tumours from 3 KrasLSL-G12D animals were collected. A total of 12 tumours were collected 
from 4 KrasLA2 animals. 8 histologically confirmed adenocarcinomas were collected from 4 
FVB/N KrasLSL-G12D animals, and 1 from a WT FVB/N animal. 13 tumours, including 10 
histologically confirmed adenocarcinomas, were collected from 7 WT A/J animals. 
KrasLSL-G12D is a latent G12D allele that is inactive in the absence of Cre-recombinase. 
Importantly, lungs from KrasLSL-G12D heterozygous mice were shown to have an 
approximately 2-fold reduction of Kras mRNA transcript and protein compared to WT 
littermates30. Furthermore, these mice had more and larger lung tumours than WT mice 
following carcinogen treatment30, similar to results seen for animals heterozygous for the 
original Kras null allele31.
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No animals or tumours were excluded from the analysis. Tumours were collected from male 
and female mice, and no sex differences were observed. No formal randomization was 
performed, and all analyses were performed against the entire set of data in an unbiased 
manner. All animal experiments were approved by the University of California San 
Francisco Laboratory Animal Resource Center.
DNA Isolation and sequencing
Formalin-fixed or flash-frozen tumours free of visible normal tissue were digested overnight 
in proteinase K (Bioline) and phenol/chloroform purified using 5 PRIME Phase Lock Gel 
Heavy Tubes (Fisher Scientific). Integrity of genomic DNA was assessed by electrophoresis 
on 1% agarose gels, and concentration was determined by nanodrop spectrophotometry and 
PicoGreen (Invitrogen). Exome enrichment and sequencing genomic libraries were prepared 
using the Illumina Paired End Sample Prep Kit following manufacturer instructions. 
Enrichment was performed as described previously32 using the Agilent SureSelect Mouse 
All Exon kit following the manufacturer’s recommended protocol. Each exome was 
sequenced using a 76bp paired-end protocol on the Illumina platform (GAII or HiSeq2000).
Sequence alignment, processing and quality control
Tumour .bam files were aligned to the GRCm38/mm10 version of the Mus musculus 
genome using BWA (version 0.5.9)33. After alignment, duplicates were marked and mate 
information was fixed using Picard (version 1.80; http://picard.sourceforge.net/). We then 
recalibrated base quality score and realigned reads around indels using GATK (version 
2.2-15)34. Finally, alignment and coverage metrics were collected using Picard. We 
sequenced an average of 75 million unique on-target reads per tumour. Targeted bases were 
sequenced to a mean depth of 72, and greater than 88% of targeted bases were sequenced to 
20× coverage or greater. There were no significant differences in depth of coverage or 
proportion of regions covered to 20× between tumour induction groups.
Identification of SNVs and annotation
SNVs were identified using the somatic variant detection program, MuTect (version 
1.1.4)35. Tumours were called against DNA taken from normal tail isolated from two WT 
FVB/N control samples. GRCm38/mm10 served as the reference during calling. Each set of 
variants was then subset to those variants that passed MuTect filters and had a minimum 
read depth of 12. The intersection of both callsets was then filtered for known variants from 
the database of mouse variation available at ftp-mouse.sanger.ac.uk (release 1303, mgp.v3). 
Variants found only in Mus spretus, Mus castaneus, or Mus musculus musculus were not 
used for filtration. All samples were also filtered for variants observed in a panel of six 
controls. These comprised the two WT samples used for variant calling, two KrasLA2 mice, 
and two KrasLSL-G12D heterozygous mice. These mice were then called for variants using 
FreeBayes (version 0.9.8; http://arxiv.org/abs/1207.3907), UnifiedGenotyper (version 
2.2-15)34 and mpileup (version 0.1.18)36. Variants from each caller were then filtered for 
sites with a minimum quality of 50 and minimum depth of 10. Variants called by a 
minimum of two callers were used to filter variants. Surviving variants were annotated using 
Annovar (downloaded on 5/9/2013)37. A final level of filtration was performed on variants 
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that showed clear clustering by mouse, which were called SNPs and discarded. In 
KrasLSL-G12D mice, MNU-induced G12D mutation of the WT allele was clearly 
distinguished from latent G12D on the KrasLSL-G12D allele by observation of a nearby SNP, 
unique to the KrasLSL-G12D allele, in the exome-sequencing reads as well as Sanger 
sequencing.
Mutation spectra analysis
SNVs in all tumours were annotated by the 96 possible trinucleotide context substitutions (6 
types of substitutions × 4 possible flanking 5′-bases × 4 possible flanking 3′-bases) and 
summed in each tumour, creating a matrix of 82 tumours × 96 substitutions. For hierarchical 
clustering, these counts were converted to per tumour proportions and clustered by 
Euclidean distance and similarity computed by nearest neighbor in R. For heatmaps in Fig. 
1c and Extended Data Fig. 1, substitution counts were log10 normalized, column scaled and 
centered on 0. Mutation spectra barplots were created by dividing each totaled type of 
substitution in each tumour by the total number of successfully sequenced contexts (defined 
as ≥ 10× coverage) in that tumour corresponding to each substitution, retrieved from 
mpileup of the .bams in samtools. The resulting per-tumour substitution rates were then 
averaged across all tumours in the respective treatment groups.
Prioritization of high-likelihood driver genes
We explored a recently published gene prioritization approach that specifically addresses the 
phenomenon of spurious enrichment of longer genes by adjusting for gene expression and 
replication timing4. However, given the scarcity of recurrent variants in our dataset limiting 
the utility of this approach, we decided to prioritize variants that occurred in genes described 
by Vogelstein et al. (2013) as known to harbor bona fide driver mutations in cancer19, as 
well as the recently identified lung cancer driver genes Fgfr4, Map3k9, and Pak518. In 
particular, Vogelstein et al. described a stringent list of 125 driver genes harboring subtle 
mutations based on the criteria that >20% recorded mutations in oncogenes must be 
recurrent and missense, and >20% recorded mutations in tumour suppressors must be 
inactivating. Mtus1 was chosen for further investigation due to recurrence of missense and 
nonsense mutations. Variants were compared to known human somatic mutations as 
available via the COSMIC database38. Briefly, the mouse and human sequences for 
homologous proteins were pairwise aligned using Clustal Omega39 and the human protein 
position homologous to the mouse mutation was used to query COSMIC for known 
missense and nonsense mutations at or surrounding this peptide position. Local conservation 
was determined after sequence alignment using a +/− 10 amino acid residue window 
surrounding the substituted amino acid.
Validation of SNVs
SNVs were validated by either Sequenom MassARRAY or conventional Sanger sequencing. 
SNVs were called validated if they were detected in the tumour but not matched normal 
DNA. A subset of SNVs which failed both methods for technical reasons was called 
validated if individual inspection of the aligned reads in tumours and controls strongly 
supported validity, as performed in previous studies40. Method of validation for SNVs in 
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driver genes is noted in Extended Data Table 2 and SI Table 5. Altogether, validation was 
attempted on 401 SNVs from the adenomas. A total of 11 failed for technical reasons, and 
13 were inconclusive. A total of 17 variants were validated by visual inspection, 
representing 4.2% of the 401 variants tested. SNVs tested by Sequenom were called 
inconclusive if the SNV was observed in the tumour but failed in the control, or the SNV 
was observed in the tumour and not the matched normal control, but was observed in control 
tissue from another mouse. SNVs tested by visual inspection were called inconclusive if 
inspection suggested somatic origin, but total variant reads were less than 10. The overall 
validation rate (excluding inconclusive SNVs) was 87%. The Sequenom validation rate 
alone was 86%. The vast majority of Kras mutations were validated by Sanger sequencing, 
although a small subset went undetected by this method (SI Table 1) despite confirmation by 
manual inspection of the alignments, suggesting a higher sensitivity afforded by WES. 
These patterns confirm previous results on carcinogen-specific mutations in Kras6,9,10. 
Sanger sequencing validation was attempted on 20 randomly selected CGN>A transitions as 
well as 3 CGN>A transitions in driver genes in the adenocarcinoma samples, 15 of which 
passed (SI Table 8). Alignments were visually inspected for the remaining 8, all of which 
supported somatic origin, but only one of which had enough variant reads (>= 10) to pass. 
Interestingly, the inconclusive variants and the majority of the validated variants had very 
low variant read fractions, supporting a hypothesis that the CGN>A mutations were acquired 
during progression and are represented in subclonal tumour fractions.
Assessment of copy number from read depth
Copy number was estimated from sequencing data using FREEC (version v6.4; http://
bioinfo-out.curie.fr/projects/freec/). Read depth was compared between tumour and control 
samples to estimate copy number in 8 kb windows, and subsequently segmented via a 
LASSO based algorithm41. FREEC was run with the following parameters: window size, 8 
kb; step size, 2.5 kb; contaminationAdjustment = TRUE; noisyData = TRUE; BAF 
calculation activated. 2.5 kb windows were then aggregated into 15 kb bins by taking the 
median ratio for all covered windows. Each tumour was profiled against the two WT 
controls used for variant calling. Aggregate profiles were generated for each tumour by the 
following rules: if either ratio was approximately neutral, the region was considered neutral; 
if both ratios were aberrant with the same directionality, the more conservative ratio was 
used; if both ratios were aberrant with different directionality, the region was discarded. 
Resulting merged ratios were then inspected for high missing rates and low variance, which 
were then omitted. Additionally, several small regions with evidence of technical artifacts 
resulting in extremely consistent aberration rates (greater than 50% of samples) across all 
treatment groups were manually excluded. Particularly, these regions were manually 
inspected for the existence of large gene families that could account for misalignments and 
result in spurious aneuploidies. Short spans on chromosomes 1, 4, 6, and 12 were discarded 
as artifacts.
Histological classification
A small piece of each tumour was collected and paraffin embedded for pathology, sectioned 
to 6 μm and H&E stained. Histological architecture was classified as either papillary, solid, 
or mixed papillary and solid. Solid was defined as histology with marked lack of papillary 
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structure, yet more structure than traditionally solid lung adenocarcinomas in humans. 
Adenocarcinomas were called based on large size and the presence of the following 
cytological criteria: tumour cell crowding, scattered mitotic figures, nuclear atypia 
(enlargement and moderate pleomorphism), nuclear membrane irregularity, and prominent 
nucleoli. All histology was called by a lung pathologist blinded to the study groups and 
conditions.
Cell culture, Mtus1 knockdown, and MTT assay
The mouse lung cancer cell line K493.1, which harbors a Kras G12D mutation, was grown 
in DMEM supplemented with 10% fetal bovine serum (Atlas Biologicals). Mtus1 was 
knocked down using 50 nM ON-TARGETplus SMARTpool siRNA (Dharmacon) 
containing multiple pooled siRNAs targeting all isoform transcripts of mouse Mtus1 (Cat: 
L-065229-01). Transfection of siRNA was performed at ~20-40% cell confluence using 
Lipofectamine-2000 (Invitrogen). In parallel, cells were transfected with control ON-
TARGETplus Non-Targeting Pool siRNA (Cat: D-001810-10). RNA was harvested from 
cells at day 3 after transfection using Trizol reagent (Invitrogen), DNA was removed using 
the TURBO DNA-free kit (Ambion), and cDNA was synthesized from 500 ng RNA using 
the Superscript III First-strand Synthesis kit (Invitrogen). qRTPCR was performed on cDNA 
using TaqMan Assays-on-Demand (Applied Biosystems) against mouse Mtus1 
(Mm00628662_m1 Mtus1) and b-actin on the 7900HT Fast Real-Time PCR System 
(Applied Biosystems). Reactions were performed in quadruplicate, and levels of Mtus1 were 
normalized to b-actin. Cell proliferation was assayed in 96-well plates (six replicate wells 
per group) at days 1, 2, and 3 after siRNA transfection using MTT (Invitrogen). Formazan 
crystals were re-suspended in DMSO, and absorbance was read at 540 nm. Four independent 
experiments were performed, and a significant increase in absorbance (Wilcoxon rank-sum 
test) was always seen in the Mtus1 knockdown compared to control siRNA cells at day 3. 
One representative experiment is shown in Extended Data Fig. 5b. All protocols were 
performed following manufacturer’s instructions.
Survival analyses in human lung cancer datasets
The TCGA LUAD (human lung adenocarcinoma) and LUSC (human lung squamous cell 
carcinoma) datasets were downloaded from the UCSC Cancer Genomics Browser (https://
genome-cancer.ucsc.edu). Illumina HiSeq 2000 RNA Sequencing expression data was used 
for analyses of gene expression with overall survival. A validation dataset for MTUS1 
expression in lung adenocarcinoma24 was downloaded from https://caintegrator.nci.nih.gov/
caintegrator/. Analysis of MTUS1 expression and survival was also repeated in a second 
squamous cell carcinoma (SCC) dataset42, which was downloaded from the UCSC Cancer 
Genomics Browser. No association between MTUS1 expression and survival was seen in the 
SCC datasets (SI Table 3), suggesting that MTUS1 expression may only have prognostic 
significance in certain types of lung cancer such as NSCLC. For all survival analyses, 
clinical covariates of sex, age, cigarette pack years smoked, and stage were included, except 
in the Shedden, et al. dataset24 where cigarette pack years smoked was not available. Cox 
regression was performed in R with gene expression as a continuous variable. High and low 
expression groups were split about median expression values for plotting Kaplan-Meier 
curves.
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Human versus mouse mutation comparison
Genes included in this comparison were limited to known driver genes (see Prioritization of 
high-likelihood driver genes) harboring mutations in the carcinogen-induced mouse 
tumours. The TCGA LUAD WES .vcf was downloaded from the UCSC Cancer Genomics 
Browser (https://genome-cancer.ucsc.edu). Only functional SNVs and indels were included. 
Validated functional SNVs from carcinogen-induced mouse adenomas and 
adenocarcinomas, and CNAs from the carcinogen-induced adenomas, were used in the 
comparison. Inclusion of mouse CNAs (6 total) made little difference overall, but were 
included to emphasize recurrent mutation of Rb1 in the mouse tumours, which had four 
deletions and two missense SNVs.
Generation of plots
All plots were created using the statistical computing language R (R Core Team (2013). R: 
A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. http://www.R-project.org/). Heatmaps were generated using 
the heatmap.2 function in the gplots package (Gregory R. Warnes, et al. (2014). gplots: 
Various R programming tools for plotting data. http://CRAN.R-project.org/package=gplots), 
Kaplan-Meier curves were generated using the survival package (Therneau T (2013). A 
Package for Survival Analysis in S. http://CRAN.R-project.org/package=survival), and all 
other plots were made using the ggplot2 package (H. Wickham (2009). ggplot2: elegant 
graphics for data analysis. Springer, New York).
Statistical analyses
The nonparametric Wilcoxon rank-sum test (Mann-Whitney U test) was used in Figures 1, 
2, 4, and Extended Data Figures 2, 4, and 5 for testing the alternative hypothesis that two 
populations of values differ against the null hypothesis that they are the same. This test was 
chosen due to efficiency in handling both normal and non-normal distributions. The Fisher 
Exact test was used in the text and in Extended Data Figures 3 and 4 to compare count data 
between groups, and was chosen for its robust ability to handle high and low ranges of count 
data. Where appropriate, p-values were adjusted for multiple tests using the Holm’s 
correction for multiple comparisons. Survival analysis in Extended Data Figure 5 is 
explained in the section “Survival analyses in human lung cancer datasets”. All data were 
visualized in R using summary statistics and basic plotting functions prior to statistical 
testing, and variance was comparable in all cases where the Wilcoxon rank-sum test was 
used. All assumptions of statistical tests were met.
Data deposition
The raw .bam files are available at ENA (accession ERP001454). A sample ID key with 
study names and ENA names is provided in supplementary information 
(ExomeLungTumorIDs_Key.txt). Variant call format files of SNVs used in analyses in the 
paper are provided in supplementary information (Adenomas_variants.txt, 
Adenocarcinomas_variants.txt).
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Extended Data
Extended Data Figure 1. Distinct and consistent mutation spectra across tumours from 
carcinogen and genetic models
a-c, Stacked heatmaps displaying the mutation spectra of all MNU-induced, a, urethane-
induced, b, and KrasLA2, c, tumours, shown as normalized frequencies of all 96 possible 
substitutions. Substitutions are shown below each heatmap, with 5′- and 3′-flanking base 
context displayed on the top and right, respectively. Tumour ID is shown to the left of each 
heatmap.
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Extended Data Figure 2. Highly specific mutation signatures
a, Breakdown of G>A transitions in MNU-induced tumours. 5′-flanking purine versus 
pyrimidine G>A substitutions, and 3′-flanking thymidine versus all other G>A substitutions, 
are highly significant (p < 0.0003, Wilcoxon rank-sum test). b-c, Breakdowns of A>G 
transitions, b, and A>T transversions, c, in urethane-induced tumours. d-e, All 96 
substitutions in urethane-induced, d, and KrasLA2 tumours, e. In e, the CGN>A (NCG>T) 
signature mutations of genomic instability are denoted. Mutation counts per tumour were 
normalized to total length of sequenced trinucleotide contexts in each tumour and averaged. 
Error bars represent SEM.
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Extended Data Figure 3. Kras G12D induces tumours with different histologies than codon 61 
mutants
a, Representative papillary, solid, and mixed tumour histologies (200× magnification). b, 
Breakdown of different histologies in each treatment group. Histologies from KrasLA2 and 
MNU groups were significantly different than those from urethane, but there was no 
significant difference between KrasLA2 and MNU (Fisher Exact test, Holm’s correction for 
multiple comparisons).
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Extended Data Figure 4. Germline Kras genotype influences mutation specificity in urethane-
induced tumours
a, Kras mutant alleles for urethane tumours are plotted as colored squares for all three 
oncogenic alleles detected in these tumours. Kras genotype is indicated as either white (WT) 
or black (heterozygous) squares. b, Highly significant switch in Kras codon 61 mutations 
between tumours from WT mice and Kras+/− mice (Fisher Exact test). c, No significant 
difference was seen between the exome-wide rates of causative Kras Q61R (CAA>G) and 
Q61L (CAA>T) mutations between tumours from WT and Kras+/− mice (Wilcoxon rank-
sum test).
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Extended Data Figure 5. MTUS1 is a tumour suppressor in mouse and human lung cancer
a, qRT-PCR quantification of siRNA knockdown of Mtus1 in a Kras G12D mouse lung 
cancer cell line (K493.1) (Wilcoxon rank-sum test). b, MTT assay shows increased growth 
following Mtus1 knockdown (Wilcoxon rank-sum test). Four independent trials were 
performed and growth was significantly increased by day 3 after knockdown in each 
experiment. One representative trial is shown. c, MTUS1 expression is significantly 
associated with overall survival in human lung adenocarcinoma, p=0.00097, X2=10.9. 
Analysis was performed using clinical covariates gender, age, pack years smoked, and stage.
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Extended Data Figure 6. Proportion of tumours with CNAs in each treatment group
Amplifications and deletions were defined as regions with a log2 ratio greater than 0.5 or 
less than −0.5, respectively. Chromosomes are arranged on the X axis in a head-to-tail 
formation.
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Extended Data Figure 7. Histological confirmation of lung adenocarcinomas
a-b, Representative histologies (400× magnification) of A/J, a, and FVB/N, b, 
adenocarcinomas. Zoom insets show tumour cell crowding and scattered mitotic figures 
(black arrowheads), nuclear atypia including enlargement and moderate pleomorphism, 
nuclear membrane irregularity, and prominent nucleoli. Scale bar = 20 μm.
Extended Data Figure 8. Comparison of urethane-signature mutations in adenomas and 
adenocarcinomas
Urethane A>G transitions (left) and A>T transversions (right) are shown in A/J 
adenocarcinomas, FVB/N adenocarcinomas, and FVB/N adenomas. Mutation counts per 
tumour were normalized to total length of sequenced trinucleotide contexts in each tumour 
and averaged. Error bars represent SEM.
Extended Data Table 1
Treatment groups and lung tumours for WES
Treatment Kras Genotype Tumours (n) Kras mutations
Urethane
WT 18 Q61R/L/H
Het 26 Q61R/L/H
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Treatment Kras Genotype Tumours (n) Kras mutations
MNU
WT 5 G12D
Het 21 G12D
None LA2 12 G12D
Extended Data Table 2
Mouse lung adenoma SNVs in established cancer driver 
genes and Mtus1
Chr Position Gene Exon Substitution Consequence Observed Tumours Validated Validation Method*
12 112662237 Akt1 3 GGA>A E40K 1 1024T10 Yes Both
17 72603313 Alk 1 GGG>A G133R 1 1024T8 Yes Sequenom
18 34316299 Apc 16 TGT>A Q2083X 1 1024T8 Yes Inspection
4 133720797 Arid1a 3 GGA>A S520F 1 1024T6 Yes Sanger
4 133686649 Arid1a 15 GAC>G D1287G 1 33T4 Yes Sanger
17 5097671 Arid1b 3 GGG>A P564L 1 1045T4 Yes Sequenom
17 5337117 Arid1b 18 AGA>A S1563F 1 1024T3 Yes Sequenom
17 5337249 Arid1b 18 GGA>A S1607F 1 1024T7 Yes Sequenom
2 153393885 Asxl1 9 GGG>A G296R 1 1024T2 Yes Sequenom
2 153397578 Asxl1 11 GGC>A P430S 1 1024T4 Yes Sequenom
9 53460891 Atm 46 AGG>A R2200K 1 75T3 Yes Sequenom
9 53511883 Atm 13 AGA>A E648K 1 1024T8 Yes Sequenom
9 53518635 Atm 9 AGA>A S367F 1 1024T4 Yes Both
X 105875634 Atrx 9 GGG>A G867R 1 1024T3 Yes Sequenom
17 26190206 Axin1 8 AGC>A A727T 1 1039T3 Yes Inspection
11 101549022 Brca1 2 GGA>A P25S 1 1024T7 Yes Sequenom
5 150558455 Brca2 21 GGA>A D2821N 1 1045T1 Yes Sequenom
5 140882326 Card11 19 GGA>C E856Q 1 1045T2 Yes Inspection
9 44164145 Cbl 8 GGA>A S401F 1 1024T9 Yes Sanger
7 25286003 Cic 6 AGG>A G291R 1 1012T3 Yes Inspection
7 25287831 Cic 9 GGG>A G481E 1 1024T5 Yes Inspection
16 4085706 Crebbp 31 GGT>A P1890S 1 1024T7 Yes Sequenom
16 4094715 Crebbp 24 GGG>A P1353S 1 1024T3 Yes Sequenom
16 4117340 Crebbp 14 GGT>A T933I 1 1024T1 Yes Sequenom
17 33913569 Daxx 6 AGA>A D596N 1 1024T2 Yes Inspection
12 3899919 Dnmt3a 10 AGC>A A352T 1 1045T4 Yes Sequenom
15 81628398 Ep300 15 GGA>A E974K 1 1024T5 Yes Inspection
X 95428261 Fam123b 2 AGT>A V84I 1 1024T4 Yes Inspection
7 130196315 Fgfr2 9 CAG>G C401R 1 1012T3 Yes Inspection
5 33733951 Fgfr3 12 GGC>A A539T 1 1024T1 Yes Sequenom
5 33733706 Fgfr3 11 GGT>A V482I 1 1024T5 Yes Sanger
13 55160082 Fgfr4 7 GGC>A A293V 1 1045T7 Yes Inspection
5 147344556 Flt3 19 TGA>A E789K 1 1045T4 Yes Sequenom
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Chr Position Gene Exon Substitution Consequence Observed Tumours Validated Validation Method*
6 88204692 Gata2 5 TAC>G Y376C 1 1024T3 Yes Sequenom
2 9874578 Gata3 3 GGA>A E196K 1 1045T4 Yes Sequenom
5 114952618 Hnf1a 7 GGG>A P487S 1 1045T5 Yes Sequenom
1 65161862 Idh1 7 GGC>A G310D 1 1012T3 Yes Inspection
19 29302040 Jak2 21 AGT>A V1010I 1 1024T10 Yes Sequenom
X 152268847 Kdm5c 19 CAG>T Q902L 1 33T4 Yes Sanger
X 152271108 Kdm5c 23 GAC>G T1179A 1 35T1 Yes Sanger
5 75647780 Kit 15 AGG>A P728L 1 1024T2 Yes Sequenom
4 55530863 Klf4 3 CAG>G S83G 1 1800T2 Yes Sequenom
13 111758076 Map3k1 11 AGA>A D689N 1 1026T1 Yes Inspection
12 81780619 Map3k9 1 GGG>A G86S 1 1026T2 Yes Sanger
12 81724480 Map3k9 10 GGT>A T778I 1 1026T1 Yes Sanger
12 81772793 Map3k9 2 AGG>A R229K 1 75T1 Yes Sanger
X 101294069 Med12 41 TAC>G T1985A 1 33T2 Yes Sequenom
19 6336766 Men1 3 AGG>A G169R 1 1024T2 Yes Sequenom
6 17562227 Met 19 CAA>C K1196Q 1 1790T1 Yes Sequenom
15 98852106 Mll2 32 GGG>A P2569S 1 1024T4 Yes Sequenom
15 98859560 Mll2 15 GGC>A A1352T 1 1026T2 Yes Sequenom
11 62343219 Ncor1 30 AGA>A E1441K 1 1026T2 Yes Sequenom
11 79425592 Nf1 13 TGT>A C491Y 1 1024T3 Yes Sequenom
3 98100211 Notch2 8 GGG>A P426S 1 1045T2 Yes Sequenom
4 44691909 Pax5 3 GGG>A W112* 1 1024T10 Yes Both
5 75181651 Pdgfra 15 AAT>T N711I 1 309T1 Yes Sequenom
5 75187929 Pdgfra 19 TGA>A D877N 1 1045T1 Yes Sequenom
17 20962623 Ppp2r1a 13 GGG>A P523L 1 1024T7 Yes Sequenom
13 63525046 Ptch1 17 AAC>G N915S 1 1T2 Yes Inspection
14 73206017 Rb1 22 GGA>A S766F 1 1024T7 Yes Inspection
14 73206083 Rb1 22 GGA>A S744F 1 1024T5 Yes Inspection
6 118164756 Ret 17 AGG>A R970K 1 1024T5 Yes Inspection
11 87731186 Rnf43 9 AGA>A R371K 1 1024T8 Yes Inspection
1 55012160 Sf3b1 6 GGT>A T203I 1 1045T4 Yes Sequenom
10 19011651 Tnfaip3 2 GGT>A T42I 1 1026T2 Yes Sanger
8 41083460 Mtus1 2 GGG>A W406* 1024T5, 1011T1 Yes Both
8 41084181 Mtus1 2 CGT>A T166M 1 1024T7 Yes Both
8 41015397 Mtus1 7 GGG>A G902R 1 1039T4 Yes Both
*Validation Method: Both = Sequenom MassArray and Sanger sequencing. Inspection = manual inspection of alignments
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Differences in mutation burden and spectra between carcinogen and genetic models
a, Total SNVs per tumour. Light shades denote Kras+/− genotype. All comparisons of SNVs 
between treatment groups were significant (p ≤ 1.0×10−6, Wilcoxon rank-sum test, Holm’s 
correction). No significant differences were observed between WT and Kras+/− tumours. b, 
Unsupervised, hierarchical clustering of tumours by trinucleotide context substitutions. c, 
Stacked heatmaps of mutation spectra for five representative MNU-induced and urethane-
induced tumours (see Extended Data Fig. 1 for all tumours). Substitutions are shown below 
each heatmap, with 5′ and 3′ flanking base displayed on top and right, respectively.
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Figure 2. Distinct copy number profiles of genetically- and chemically-induced tumours
Unsupervised, hierarchical clustering of log2 transformed read count ratios. KrasLA2 
tumours showed a significantly higher number of CNAs compared to carcinogen-induced 
tumours (p = 4.3−10, Wilcoxon rank-sum test). Chromosomes are aligned head to tail on the 
X axis, starting at the left. Samples are labeled by treatment and genotype, with Kras+/− 
samples appearing as light blue and light red. Sample SNV burden is displayed along the Y 
axis in greyscale.
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Figure 3. Consequential SNVs in high-likelihood driver genes only occur in carcinogen-induced 
tumours
All missense and nonsense SNVs, amplifications, and deletions in genes listed in Extended 
Data Table 2 are displayed. KrasLA2, urethane-, and MNU-induced tumours are denoted 
above in green, blue, and red, respectively, with lighter shading denoting Kras+/− genotype. 
SNVs with unequivocal evidence of consequence are bordered in black. All SNVs, 
excepting those marked with an asterisk, are concordant with the signature mutations of the 
inducing carcinogen. The bottom panel shows total SNVs per tumour (NS = 
nonsynonymous, S = synonymous).
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Figure 4. Adenocarcinomas show enrichment for a signature of genomic instability
Breakdown of G>A transitions in A/J and FVB/N adenocarcinomas reveals significant 
increases in CGN>A (NCG>T) transition rates over FVB/N adenomas (p = 0.00047 and 
0.0143, respectively, Wilcoxon rank-sum), despite similar rates and patterns of other G>A 
transitions. Mutation counts per tumour were normalized to total length of sequenced 
trinucleotide contexts in each tumour and averaged. Error bars represent SEM.
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